Parp inhibition restores extrinsic apoptotic sensitivity in glioblastoma

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Karpel Massler, Georg ^a   Pareja, Fresia ^a   Aimé, Pascaline ^a   Shu, Chang ^a   Chau, Lily ^a   Westhoff, Mike Andrew ^b   Halatsch, Marc Eric ^b   Crary, John F ^a   Canoll, Peter ^a   Siegelin, Markus D ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CCAAT ENHANCER BINDING PROTEIN; DEATH RECEPTOR 5; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SMALL INTERFERING RNA; DDIT3 PROTEIN, HUMAN; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BAX; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; ASTROCYTE; BREAST CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; FLOW CYTOMETRY; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DEFICIENCY; DRUG EFFECTS; DRUG INTERACTION; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEURAL STEM CELL; PATHOLOGY; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL LINE; UPREGULATION;

MURINAE;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MICE; NEURAL STEM CELLS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; POLY(ADP-RIBOSE) POLYMERASES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR CHOP; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919632811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114583     Document Type: Article

References (43)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996.
2. von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C, et al. (2011) Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol 29: 2150-2157.
3. Gan A, Green AR, Nolan CC, Martin S, Deen S (2013) Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol 44: 1638-1647.
4. Murai J, Zhang Y, Morris J, Ji J, Takeda S, et al. (2014) Rationale for Poly(ADP-ribose) Polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. J Pharmacol Exp Ther 349: 408-416.
5. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, et al. (2009) In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 15: 607-612.
6. Hastak K, Alli E, Ford JM (2010) Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res 70: 7970-7980.
7. Siegelin MD, Reuss DE, Habel A, Rami A, von Deimling A (2009) Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol 11: 122-131.
8. Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, et al. (2010) A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 16: 671-677.
9. Capper D, Gaiser T, Hartmann C, Habel A, Mueller W, et al. (2009) Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. Acta Neuropathol 117: 445-456.
10. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, et al. (2010) Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 16: 2715-2728.
11. Pareja F, Macleod D, Shu C, Crary JF, Canoll PD, et al. (2014) PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through down-regulation of Mcl-1 and phospho-BAD. Mol Cancer Res 12: 987-1001.
12. Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, et al. (2011) Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest 121: 1349-1360.
13. Mihaliak AM, Gilbert CA, Li L, Daou MC, Moser RP, et al. (2010) Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett 296: 168-177.
14. Gilbert CA, Daou MC, Moser RP, Ross AH (2010) Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70: 6870-6879.
15. Siegelin MD (2012) Utilization of the cellular stress response to sensitize cancer cells to TRAILmediated apoptosis. Expert Opin Ther Targets 16: 801-817.
16. Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, et al. (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344: 1396-1401.
17. Jensen SA, Calvert AE, Volpert G, Kouri FM, Hurley LA, et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111: 5682-5687.
18. Xu S, Wei J, Wang F, Kong LY, Ling XY, et al. (2014) Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst 106: dju162.
19. Happold C, Roth P, Silginer M, Florea AM, Lamszus K, et al. (2014) Interferon-beta induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther 13: 948-961.
20. Stuckey DW, Shah K (2013) TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med 19: 685-694.
21. Newsom-Davis T, Prieske S, Walczak H (2009) Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607-623.
22. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, et al. (2013) Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med 5: 171ra117.
23. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, et al. (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 16: 5386-5397.
24. Merchant MS, Geller JI, Baird K, Chou AJ, Galli S, et al. (2012) Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors. J Clin Oncol 30: 4141-4147.
25. Tolcher AW, Mita M, Meropol NJ, von Mehren M, Patnaik A, et al. (2007) Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25: 1390-1395.
26. Trarbach T, Moehler M, Heinemann V, Kohne CH, Przyborek M, et al. (2010) Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer 102: 506-512.
27. von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, et al. (2014) Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 15: 188-196.
28. Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, et al. (2004) Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64: 6858-6862.
29. Elias A, Siegelin MD, Steinmuller A, von Deimling A, Lass U, et al. (2009) Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas. Clin Cancer Res 15: 5457-5465.
30. Eckhardt I, Roesler S, Fulda S (2013) Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis 4: e936.
31. Lin T, Chen Y, Ding Z, Luo G, Liu J, et al. (2013) Novel insights into the synergistic interaction of a thioredoxin reductase inhibitor and TRAIL: the activation of the ASK1-ERK-Sp1 pathway. PLoS One 8: e63966.
32. Edagawa M, Kawauchi J, Hirata M, Goshima H, Inoue M, et al. (2014) Role of activating transcription factor 3 (ATF3) in endoplasmic reticulum (ER) stress-induced sensitization of p53-deficient human colon cancer cells to tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through up-regulation of death receptor 5 (DR5) by zerumbone and celecoxib. J Biol Chem 289: 21544-21561.
33. Yuan K, Sun Y, Zhou T, McDonald J, Chen Y (2013) PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy. Clin Cancer Res 19: 4750-4759.
34. Qi L, Bellail AC, Rossi MR, Zhang Z, Pang H, et al. (2011) Heterogeneity of primary glioblastoma cells in the expression of caspase-8 and the response to TRAIL-induced apoptosis. Apoptosis 16: 1150-1164.
35. Lavrik IN, Mock T, Golks A, Hoffmann JC, Baumann S, et al. (2008) CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J Biol Chem 283: 26401-26408.
36. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, et al. (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13: 3403-3412.
37. Palacios C, Yerbes R, Lopez-Rivas A (2006) Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 66: 8858-8869.
38. El-Zawahry A, McKillop J, Voelkel-Johnson C (2005) Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5: 2.
39. Bangert A, Cristofanon S, Eckhardt I, Abhari BA, Kolodziej S, et al. (2012) Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP. Oncogene 31: 4677-4688.
40. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815.
41. MacFarlane M, Merrison W, Bratton SB, Cohen GM (2002) Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277: 36611-36616.
42. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, et al. (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
43. Song JH, Kandasamy K, Kraft AS (2008) ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 283: 25003-25013.